MoonLake Immunotherapeutics
MLTX13.830USD
-0.040-0.29%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
881.03MMarket Cap
LossP/E TTM
More Details of MoonLake Immunotherapeutics Company
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
MoonLake Immunotherapeutics Info
Ticker SymbolMLTX
Company nameMoonLake Immunotherapeutics
IPO dateOct 20, 2020
CEOSantos Da Silva (Jorge)
Number of employees100
Security typeOrdinary Share
Fiscal year-endOct 20
AddressDorfstrasse 29
CityZUG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountrySwitzerland
Postal code6300
Phone41415108022
Websitehttps://moonlaketx.com/
Ticker SymbolMLTX
IPO dateOct 20, 2020
CEOSantos Da Silva (Jorge)
Company Executives of MoonLake Immunotherapeutics
Name
Name/Position
Position
Shareholding
Change
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Ms. Catherine Moukheibir
Ms. Catherine Moukheibir
Independent Director
Independent Director
--
--
Dr. Ramnik Xavier
Dr. Ramnik Xavier
Independent Director
Independent Director
--
--
Mr. Spike N. Loy, J.D.
Mr. Spike N. Loy, J.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Kristian Reich
Dr. Kristian Reich
Chief Scientific Officer
Chief Scientific Officer
2.93M
-6.49%
Dr. Jorge Santos Da Silva
Dr. Jorge Santos Da Silva
Chief Executive Officer, Director
Chief Executive Officer, Director
2.88M
-6.50%
Mr. Matthias Bodenstedt
Mr. Matthias Bodenstedt
Chief Financial Officer
Chief Financial Officer
627.54K
+1.76%
Mr. Simon Sturge
Mr. Simon Sturge
Independent Chairman of the Board
Independent Chairman of the Board
171.98K
--
Dr. Andrew J. Phillips
Dr. Andrew J. Phillips
Independent Director
Independent Director
--
--
Dr. Atif Khan
Dr. Atif Khan
Director - Strategic Planning and Projects
Director - Strategic Planning and Projects
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 1
Updated: Mon, Dec 1
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
Other
54.61%
Shareholders
Shareholders
Proportion
BVF Partners L.P.
27.67%
Deep Track Capital LP
6.46%
Santos da Silva (Jorge)
4.31%
Reich (Kristian)
4.15%
Avoro Capital Advisors LLC
2.80%
Other
54.61%
Shareholder Types
Shareholders
Proportion
Hedge Fund
47.09%
Individual Investor
9.25%
Investment Advisor
6.20%
Investment Advisor/Hedge Fund
5.92%
Research Firm
1.10%
Venture Capital
0.49%
Bank and Trust
0.10%
Pension Fund
0.04%
Other
29.81%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
336
52.26M
73.22%
-13.87M
2025Q2
326
71.15M
112.06%
-8.45M
2025Q1
329
71.47M
112.59%
-8.98M
2024Q4
308
74.57M
117.86%
+1.09M
2024Q3
292
73.42M
116.42%
+551.38K
2024Q2
282
72.21M
114.78%
+1.82M
2024Q1
274
70.82M
112.58%
-306.27K
2023Q4
260
64.82M
107.09%
-2.17M
2023Q3
219
60.33M
114.64%
-5.55M
2023Q2
175
60.28M
100.54%
+9.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BVF Partners L.P.
19.75M
31.1%
--
--
Jun 30, 2025
Santos da Silva (Jorge)
3.08M
4.85%
--
--
Mar 15, 2025
Reich (Kristian)
3.13M
4.93%
+48.98K
+1.59%
Sep 02, 2025
Avoro Capital Advisors LLC
4.15M
6.54%
+1.38M
+49.81%
Jun 30, 2025
Cormorant Asset Management, LP
1.99M
3.14%
-6.50M
-76.52%
Sep 30, 2025
Bodenstedt (Matthias)
616.67K
0.97%
--
--
Mar 15, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ALPS Medical Breakthroughs ETF
0.27%
Global X Guru Index ETF
0.22%
Virtus LifeSci Biotech Clinical Trials ETF
0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.02%
Strive Small-Cap ETF
0.02%
Nuveen ESG Small-Cap ETF
0.02%
iShares Morningstar Small-Cap ETF
0.01%
John Hancock Multifactor Small Cap ETF
0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
View more
ALPS Medical Breakthroughs ETF
Proportion0.27%
Global X Guru Index ETF
Proportion0.22%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.16%
JPMorgan BetaBuilders US Small Cap Equity ETF
Proportion0.02%
Strive Small-Cap ETF
Proportion0.02%
Nuveen ESG Small-Cap ETF
Proportion0.02%
iShares Morningstar Small-Cap ETF
Proportion0.01%
John Hancock Multifactor Small Cap ETF
Proportion0.01%
iShares ESG Aware MSCI USA Small-Cap ETF
Proportion0.01%
Fidelity Nasdaq Composite Index ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of MoonLake Immunotherapeutics?
The top five shareholders of MoonLake Immunotherapeutics are:
BVF Partners L.P. holds 19.75M shares, accounting for 31.10% of the total shares.
Santos da Silva (Jorge) holds 3.08M shares, accounting for 4.85% of the total shares.
Reich (Kristian) holds 3.13M shares, accounting for 4.93% of the total shares.
Avoro Capital Advisors LLC holds 4.15M shares, accounting for 6.54% of the total shares.
Cormorant Asset Management, LP holds 1.99M shares, accounting for 3.14% of the total shares.
BVF Partners L.P. holds 19.75M shares, accounting for 31.10% of the total shares.
Santos da Silva (Jorge) holds 3.08M shares, accounting for 4.85% of the total shares.
Reich (Kristian) holds 3.13M shares, accounting for 4.93% of the total shares.
Avoro Capital Advisors LLC holds 4.15M shares, accounting for 6.54% of the total shares.
Cormorant Asset Management, LP holds 1.99M shares, accounting for 3.14% of the total shares.
What are the top three shareholder types of MoonLake Immunotherapeutics?
The top three shareholder types of MoonLake Immunotherapeutics are:
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
BVF Partners L.P.
Deep Track Capital LP
Santos da Silva (Jorge)
How many institutions hold shares of MoonLake Immunotherapeutics (MLTX)?
As of 2025Q3, 336 institutions hold shares of MoonLake Immunotherapeutics, with a combined market value of approximately 52.26M, accounting for 73.22% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -38.84%.
What is the biggest source of revenue for MoonLake Immunotherapeutics?
In --, the -- business generated the highest revenue for MoonLake Immunotherapeutics, amounting to -- and accounting for --% of total revenue.
